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Background Sporadic vascular malformations (VMs) are complexcongenital anomalies of 
blood vessels that lead to stroke, life-threatening bleeds, disfigurement, overgrowth, and/or 
pain. Therapeutic options are severely limited and multi-disciplinary management remains 
challenging, particularly for high-flowarteriovenous malformations (AVM). 
Project To investigate the pathogenesis of 160 sporadic VMs in which known genetic causes 
had been excluded, sequencing of affected tissue DNA was undertaken using deep next 
generation sequencing with analysis optimised for detection of low mutant allele frequency. 
Results Mosaic activating variants in KRAS, NRAS, BRAF and MAP2K1 were identified, most 
commonly in AVM, both intracranialand extracranial. Transgenic zebrafish expressing 
BRAFV600E only in the vasculature recapitulated the human phenotype. Treatment of 
zebrafish with the BRAF inihibitor, vemurafinib, restored blood flow in AVM. 
Conclusions These findings reveal an important unifying cause of sporadic vascular 
malformations of different clinical types, and offer the potential of personalised medical 
treatment for affected individuals by repurposing of existing licensed cancer therapies. 
